NCT02974816 is a NA clinical trial of Glooko's mobile application in Diabetes Mellitus, Type 2, sponsored by Glooko.

Who is sponsoring NCT02974816?

NCT02974816 is sponsored by Glooko.

What drugs are being tested in NCT02974816?

Interventions in NCT02974816: Glooko's mobile application.

What condition does NCT02974816 study?

NCT02974816 studies Diabetes Mellitus, Type 2.

Is NCT02974816 still recruiting?

NCT02974816 is currently completed. Last updated 3 June 2021.

Last reviewed 2021-06-03 · How we verify

NCT02974816

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glooko mHealth Advantage Study

Completed NA Last updated 3 June 2021

What this trial tests

NA trial testing Glooko's mobile application in Diabetes Mellitus, Type 2 in 197 participants. Completed in 17 April 2020.

Timeline

15 May 2017

Primary endpoint
17 April 2020

17 April 2020

Quick facts

Lead sponsor	Glooko
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	197
Start date	15 May 2017
Primary completion	17 April 2020
Estimated completion	17 April 2020
Sites	4 locations across United States

Drugs / interventions tested

Glooko's mobile application

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Glooko

Who can join

Adults 18 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Glooko trials

Trials by the same sponsor.

NCT03091712 — Insulin Degludec Titration Using Mobile Insulin Dosing System · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974816 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glooko
Last refreshed: 3 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing